MindBio Completes Manufacture of Next-Generation Voice AI Intoxication Detection Kiosk

VANCOUVER, British Columbia, Oct. 14, 2026 /CourierPR/ -- MindBio Therapeutics Corp. has completed the manufacture of its next-generation Edge AI Intoxication Detection Kiosk, marking a significant step in the company’s journey towards commercializing its voice analytics technology. The new kiosk, an improvement over an initial prototype produced in June, is designed to support MindBio's proprietary Voice AI intoxication detection technology.

The company is currently refining and testing its software, which analyzes the characteristics of the human voice to predict potential impairment associated with drug and alcohol consumption. This software integration is part of MindBio's broader efforts to validate its predictive AI models against established drug and alcohol testing methods, such as breath alcohol testing and oral fluid testing. The goal is to evaluate the technology's accuracy, reliability, and suitability for commercial applications.

MindBio's Edge AI Intoxication Detection Kiosk is being developed as a rapid, non-invasive, and scalable solution for screening potential drug and alcohol intoxication. The technology aims to address the significant operational and financial challenges faced by industries that require regular or high-volume screening, such as mining, aviation, construction, heavy transport, law enforcement, and other safety-critical environments.

Traditional drug and alcohol testing methods can be labor-intensive, time-consuming, physically invasive, and expensive to administer at scale. MindBio believes its Voice AI technology has the potential to transform workplace intoxication screening by enabling organizations to assess larger numbers of individuals more efficiently, at potentially lower costs, and with minimal physical intervention.

The company's longer-term vision is to deliver an accessible, AI-powered screening solution that can be deployed across multiple workplace environments, supporting more frequent screening, improved operational efficiency, and enhanced workplace safety. By reducing the time, cost, and logistical barriers associated with conventional testing, MindBio aims to make intoxication risk screening more accessible and scalable, ultimately contributing to the prevention of workplace accidents and injuries associated with drug and alcohol impairment.

MindBio is now focused on validating its prediction models, integrating software, and progressing towards a potential first commercial pilot later this year. The pilot will further evaluate the technology in a real-world operating environment against existing on-site testing methods. The company's ambition is to develop a commercially scalable technology that addresses a significant global market opportunity and helps organizations create safer workplaces and ultimately save lives.